INTRODUCTION
The term sphingolipid-activator protein (SAP) was coined by Wenger & Inui (1984) to describe a group of low-molecular mass (glyco)proteins which stimulate the hydrolysis of sphingolipids. To date, the best characterized SAPs are SAP-1, SAP-2 and SAP-3. First described by Mehl & Jatzkewitz (1964) as an activator for cerebroside sulphatase (cerebroside 3-sulphate 3-sulphohydrolase; EC 3.1.6.8), SAP-1 has also been shown to stimulate the hydrolysis of GM, ganglioside and globotriaosylceramide (Li et al., 1985; Vogel et al., 1987) and probably has even broader specificity (Li et al., 1988) . A distinct activator, SAP-3, appears to be specific for two substrates (ganglioside GM2 and glycolipid GA2 of fl-hexosaminidase (Conzelmann & Sandhoff, 1979) . SAP-2 was first isolated by Ho & O'Brien (1971) as a ,J-glucocerebrosidase (D-glucosyl-N-acylsphingosine glucohydrolase; EC 3.2.1.45) activator and has since been shown also to stimulate the hydrolysis of f8-galactocerebroside and sphingomyelin in vitro Poulos et al., 1984 ; Paton & Poulos, 1988) . Unlike (Conzelmann & Sandhoff, 1979; Conzelmann et al., 1982) and SAP-I (Fischer & Jatzkewitz, 1978) , which act by solubilizing their lipid substrates, SAP-2 appears to act by interacting with the enzyme (Ho, 1975; Berent & Radin, 198 la,b; Prence et al., 1985) . Immunocytochemical studies have shown that SAP-1 is largely confined to lysosomes in cells from human liver and colon (Tamaru et al., 1986) as is SAP-2 in cultured human skin fibroblasts (Paton et al., 1990) .
In recent years considerable advances have been made in our understanding of the molecular genetics of the SAPs. In particular, it has been shown that SAP-1 and SAP-2 are formed from the same precursor protein (Furst et al., 1988; . Two other putative activators, saposin A (Morimoto et al., 1988 ) and component C (Fuirst et al., 1988) or saposin D (Morimoto et al., 1988) , are formed from the same SAP precursor [termed prosaposin by Morimoto et al. (1988) ] and flank (first and fourth domains respectively) the SAP-1 and SAP-2 region (second and third domains respectively) on the precursor . Saposin A has been shown to mimic the effects of SAP-2 on ,J-glucocerebrosidase and fl-galactocerebrosidase (D- galactosyl-N-acylsphingosine galactohydrolase; EC 3.2.1.46) in vitro (Morimoto et al., 1989) , and saposin D was reported to stimulate sphingomyelinase in vitro (Morimoto et al., 1988) . Biosynthetic studies indicate that the precursor protein is cotranslationally glycosylated to give a 65-68 kDa species, which is further glycosylated to 70-73 kDa, before it is processed to lower-molecular mass forms (Fujibayashi & Wenger, 1986a,b) . Vol. 285 Abbreviations used: FCS, fetal calf serum; MEM, minimal essential medium; MLD, metachromatic leucodystrophy; SAP, sphingolipid-activator protein; SGP-1, sulphated glycoprotein 1; 4-MU, 4-methylumbelliferyl.
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More recently, molecular biology studies have determined the structure of the SAP precursor gene (Holtschmidt et al., 1991a) .
The cDNA for SAP-3 has also been isolated (Schroder et al., 1989) and is genetically distinct from prosaposin (Fiirst etal., 1990 ).
Collardet at (1988) first noted the considerable sequence similarity between prosaposin and a 70 kDa rat secretory protein, the Sertoli sulphated glycoprotein 1 (SGP-1), and this raised the possibility that they were equivalent proteins from different species. Using antibodies to SAP-1 or SAP-2, it has been shown that the concentrations of intact, partially processed and fully processed forms of prosaposin vary between different tissues, both in humans and rats (O'Brien etal., 1988; Sano etal., 1989) The physiological significance of SAPs has been confirmed largely through the discovery of patients with sphingolipidstorage disorders, whose conditions result from a deficiency of a SAP rather than a sphingolipid hydrolase enzyme. Patients have now been described with deficiencies in the G.2-ganglioside activator (SAP-3) (Conzelmann & Sandhoff, 1978) and the GM1-ganglioside, globotriaosylceramide and cerebroside sulphate activator (SAP-1) (Shapiro et al., 1979; Stevens et al., 1981) . More recently, Christomanou et al. (1986 Christomanou et al. ( , 1989 have described two patients who had a deficiency in an A1 activator, now known to be identical with SAP-2 (Fuirst et al., 1988; O'Brien et al., 1988 ).
We have also described a patient (Harzer et al., 1989) who was deficient in immunologically cross-reacting material to SAP-2, but who was far more severely affected than the patients described by Christomanou et al. (1986, 1989) . The patient's fetal sibling was similarly affected. In view of the severity of the disease and the recent evidence that SAP-1, SAP-2 and two other putative SAPs are synthesized on a common precursor (Fiirst et al., 1988;  O'Brien et al., 1988), we hypothesized that our patient and his fetal sibling may have a defect in the SAP precursor which affected other products of the SAP precursor gene in addition to the SAP-2 locus. This has been confirmed in Dr. Sandhoff's laboratory (Schnabel et al., 1992) , where an A to T transversion has been identified in the initiation codon of the gene, the affected patient and fetal sibling being homozygous for this mutation.
We have previously shown that our patient and his fetal sibling had decreased 8-glucocerebrosidase,,-galactocerebrosidase and ceramid-ase (N-acylsphingosine deacylase; EC 3.5.1.23) activities (assayed in the presence of detergents), but that the activities were not as low as in patients with Gaucher disease, Krabbe disease and Farber disease respectively (Harzer et al., 1989) . We attributed the decreased activities of at least the first two of these enzymes to an observed deficiency in immunologically crossreacting material to SAP-2 (Harzer et al., 1989 (Schlote et al., 1991; Holtschmidt et al., 1991b Neuraminidase activity 4-MU-a-D-N-acetylneuraminide (1 mg) was dissolved in 1 ml of water and purified, by phase partitioning twice with 1 ml of ethyl acetate, immediately before use. The substrate (100 nmol dissolved in 1.6 ml of 0.05 M-sodium acetate buffer, pH 4.0) was applied to a 75 cm2 flask of cultured fibroblasts (early confluent stage with 0.6-1.0 mg of cell protein) which had been washed once with iso-osmotic NaCl and once, for 10 s, with water. After a 10, 20 and 30 min incubation at 37°C, 200, 175 and 153 ,u1 (one-eighth of the remaining volume in each case) respectively of reaction mixture was withdrawn for the determination of released 4-MU, after adjustment of the pH to 10.3 by the addition of 0.5 ml of 0.3 M-2-amino-1 -methylpropan-1-ol. Blank assays were performed in culture flasks without any cells. Protein was determined by the Lowry procedure (Lowry et al., 1951) by using homogenates of the cell layer that remained attached to each flask at the end of the assay. We have independently shown that neuraminidase remains associated with this cell layer. Specific activities were calculated from the amounts of 4-MU that were released from the substrate after 20 and 30 min, the two values being averaged. There was a steady increase in the amount of substrate that was released after 10, 20 and 30 min, although slight non-linearity was tolerated.
Chromatography and identification of radiolabelled products
For the following enzyme assays and sphingolipid-loading studies, the radioactive products were analysed by radio-t. (Lowry et al., 1951) in a final volume of 0.17 ml. The assay tubes were incubated at 25°C for 15 h. After being dried, the lipids were extracted and analysed on plastic-backed silica-gel plates. Cerebroside sulphate-loading studies [ceramide-3H] Cerebroside sulphate (600 nmol, 1 kBq/nmol) in 0.1 ml of ethanol was added to freshly confluent skin fibroblast cultures (0.2-0.5 mg of protein) in 25 cm3 culture flasks containing 5 ml of MEM with 20 % FCS. After culture at 37°C for 3 days, the medium was replaced with fresh medium, without the added sulphatide, and culture was continued for an additional day. The cell layer was washed twice with iso-osmotic NaCl and the lipids were extracted in situ for 2 h with chloroform/methanol (1:9, v/v). The extracts contained 5-11 % of the radioactivity added to the cell cultures. The lipids were analysed by radio-t.l.c. on glass-backed plates. The data were corrected for small amounts of radioactive contamination in the substrate which co-chromatographed at the solvent front (4-5 % of added radioactivity) and with the free ceramide peak (1.5 %). The glassbacked plates gave better resolution in this region than the plastic-backed plates used for the 'in vitro' enzyme assays.
Globotriaosylceramide-loading studies [ceramide-3H]Globotriaosylceramide (7 ,ug, 100 kBq/,ug) in 0.1 ml of ethanol was added to freshly confluent skin fibroblast cultures (about the second to fifth passage and about 0.2-0.4 mg of protein) in 25 cm2 culture flasks containing 5 ml of MEM with 20 % FCS. After culture at 37°C for 4 days, the medium was replaced with fresh medium, without the added globotriaosylceramide, and culture was continued for an additional day. The cell layer was washed twice with iso-osmotic NaCl and the lipids were extracted in situ with 0.7 ml of methanol for 30 min. The extract was mixed with 0.3 ml of chloroform and the mixture was used to re-extract the cell layer for 30 s. The final extracts, which contained 5-12 % of the radioactivity added to the cell cultures, were analysed on glass-backed plates.
Lactosylceramide-loading studies [ceramide-3H]Lactosylceramide (4 nmol, 40 kBq/nmol) in 60 ,ul of ethanol was added to freshly confluent skin fibroblasts cultures (0.3-0.5 mg of protein) in 25 cm2 flasks containing 5 ml of MEM with 15 % FCS. After culture at 37°C for 3 days, the cell layer was washed three times with phosphate-buffered saline (g/litre: NaCl, 8.0; KCI, 0.2; Na2HPOV, 1.15; KH2PO4, 0.2) containing EDTA and then extracted in situ with 0.7 ml of methanol for 4 h. Chloroform (0.3 ml) was then added to the methanol in the flasks. After 20 s the extract was removed and dried, then redissolved in chloroform/methanol (2: 1, v/v). The lipid extracts contained 7-10 % of the radioactivity added to the cell cultures and portions (usually one-half) were applied to plastic-backed silica-gel plates.
RESULTS

Turnover of cerebroside sulphate
Loading studies of fibroblasts with cerebroside sulphate indicated a clear defect in turnover of this substrate in cells from the patient and his fetal sibling, with a deficiency in turnover similar to that seen in cells from patients with late infantile and juvenile MLD ( Table 1 ). The result was clearly different from that seen with a juvenile Krabbe patient, where turnover of sulphatide was normal but the product of the sulphatase reaction, galactosyl- Table 2 ). The globotriaosylceramide-loading studies also indicated that the turnover of lactosylceramide was impeded in our patient and his fetal sibling, since a relatively large percentage of the metabolized radioactivity appeared in this product (43 % for the patient, 54 % for the affected fetus) compared with controls (23-29%).
Turnover of lactosylceramide Lactosylceramide-loading studies (Table 3) confirmed that turnover of this lipid was decreased in fibroblasts from the affected patient and fetus. Radioactivity from the small amount of lactosylceramide that was metabolized was largely found in the ceramide/fatty acid fraction and, unlike control incubations, virtually none appeared in biosynthetic products (sphingomyelin, phosphatidylcholine, phosphatidylethanolamine and, presumably, gangliosides at the origin). Patients with deficiencies in ,igalactosidase (EC 3.2.1.23) (GM1 gangliosidosis and galactosialidosis), 8-galactocerebrosidase (Krabbe disease) or an isolated SAP-I deficiency showed normal turnover of lactosylceramide and normal incorporation of radioactivity into biosynthetic products. In controls the incorporation of radioactivity into biosynthetic products was greater than seen for the other substrates used. (Table 1) . Other this patient (Harzer et al., 1989) . investigators (Tanaka & Suzuki, 1978; Kudoh & Wenger, 1982; Kobayashi et al., 1985a,b; Ida et al., 1990) have shown that, although there is considerable catabolism of galactosylceramide in fibroblasts from patients with Krabbe disease, the turnover of this substrate is less than in controls.
Turnover of globototriaosylceramide
Since a SAP-1 deficiency was suspected in our patient, globotriaosylceramide turnover was also investigated. In fibroblasts from both the patient and his fetal sibling the turnover of
4-MU-M-D-N-acetylneuraminide neuraminidase
In view of the suggestion that lysosomal neuraminidase may be a processed form of prosaposin, neuraminidase activity was determined in fibroblasts using an assay procedure in situ. In three experiments using cells from the patient, the activity of this enzyme was clearly normal (43, 72 and 89 nmol of neuraminide hydrolysed/h per mg of protein) when compared with controls (47.6+24.3 units, n = 14). Cells from a patient with an isolated SAP-1 deficiency also had normal activity of this enzyme. Fetal kidney sphingolipids Clear increases in monohexosylceramide, dihexosylceramide and sulphatide were seen in the kidney of the affected fetus (Fig. 1, Table 4) . Indeed, the concentration of sulphatide was similar to that found in kidney tissue from a fetus with MLD. The concentration of sphingomyelin was a little higher for the affected fetus than for the normal control, but was similar to those found in the two pathological controls (Table 4) . These results are in agreement with our previous findings on liver tissue from the patient and affected fetus, where concentrations of ceramide, glucosylceramide and lactosylceramide, but not sphingomyelin, were elevated (Harzer et al., 1989) . Although the quantitative estimations reported here (Table 4) have not been repeated in their present form, the trends observed (in particular the increases in ceramide mono-and di-hexosides and sulphatides in the affected fetus's kidney) are also apparent from a visual assessment of the anisaldehyde-stained two-dimensional chromatograms presented in Fig. 1 , and from the relative peak sizes of the relevant spots after densitometric analysis of similar two-dimensional chromatograms (results not shown). The limited supply of remaining tissue from the affected fetus has been used for a more comprehensive quantitative lipid study (V. Bradova, K. Harzer, F. Smid, B. C. Paton, B. Ulrich-Bott & W. Roggendorf, unpublished work). As part of that study the observed differences reported here have been confirmed. As noted in Table  4 , the amount of total lipid/mg dry weight varied between the samples. However, clear elevations in the concentrations of ceramide mono-and di-hexosides and sulphatide in the kidney of the affected fetus, and of sulphatide for the MLD sample, are still apparent even when the data are expressed relative to the total lipid content rather than tissue dry weight.
DISCUSSION
Molecular biology studies of prosaposin cDNA from members of the present family have indicated that the affected siblings are homozygous for a defect in the initiation codon (Schnabel et al., 1992) . It is unlikely therefore that any prosaposin gene products are produced in this disorder, since the next in-frame AUG codon is within the saposin A domain. In addition, no biosynthesis of prosaposin products has been detected with anti-(SAP-1) and anti-(SAP-2) sera [Schnabel et al. (1992) and our own preliminary findings with a different anti-(SAP-2) serum].
Previously, we have provided biochemical and immunological evidence that SAP-2 is deficient in this disorder (Harzer et al., 1989; Paton et al., 1990) . Biochemical evidence of an additional SAP-1 deficiency in our patient and his fetal sibling comes from the following observations. First, both sulphatide and globotriaosylceramide turnover were decreased in fibroblasts from the patient and his fetal sibling, but cerebroside sulphatase and globotriaosylceramide a-galactosidase activities were normal when measured in vitro in the presence of bile salts. Second, a kidney sample from the affected fetus showed a clear increase in sulphatide. The deficiency in SAP-I has been confirmed immunologically in Dr. Sandhoffs laboratory (Schnabel et al., 1992) .
Five other patients with SAP-I deficiencies (two from one family) have been reported in the literature as variants of MLD (Shapiro et al., 1979; H-ahn et al., 1982; Wenger et al., 1989; Schlote et al., 1991) . They also all showed a deficiency in sulphatide turnover in fibroblasts associated with a normal or near-normal activity of arylsulphatase A or cerebroside sulphatase in leucocyte and/or fibroblast extracts. Considerable phenotypic differences between the cases were noted (Wenger et al., 1989) . Increases in globotriaosylceramide, indicating a problem with the catabolism of this lipid, have also been reported for some of the patients (Li et al., 1985; Wenger et al., 1989) .
SAP-I has also been shown to stimulate the -hydrolysis of GM1 ganglioside in vitro (Li et al., 1985; Banks et al., 1987; Vogel et al., 1987) . However, GM1 accumulation has not been an apparent feature of the previously described cases of SAP-1 deficiency (Hahn et al., 1982; Li et al., 1985; Wenger et al., 1989; Schlote et al., 1991) , with even the most severely affected case (Wenger et al., 1989) having little or no accumulation of GMl ganglioside in the brain. Recent studies h-ave indicated that the turnover of GM1 ganglioside to GM2 ganglioside was close to normal in fibroblasts from our patient (Schmid et al., 1992) , making it unlikely that SAP-1 is essential for GM, ganglioside catabolism in vivo.
The clinical history of our patient (Harzer et al., 1989 ) indicated a more severe disorder than reported for the other cases of either SAP-2 deficiency (Christomanou et al., 1986 or SAP-I deficiency (Shapiro et al., 1979; Hahn et al., 1982; Schlote et al., 1991 ; Wenger et al., 1989) . This presumably reflects the combined deficiency of these two activators, and possibly the other prosaposin gene products, in this disorder. Whereas the increase in sulphatide in the kidney of our affected fetus can be explained by a deficiency in SAP-I and the increase in monohexosylceramide by a deficiency in SAP-2, the increased concentration of dihexosylceramide probably reflects the combined activator deficiency. Increases in dihexosylceramides, in some instances in both the lactosyl and digalactosyl forms, have sometimes been reported in SAP-1 deficiency, but they have not been consistently observed (see Shapiro et al., 1979; . Li et al., 1985; Wenger et al., 1989; Schlote et al., 1991) . Digalactosylceramide with an a-linked terminal galactose residue accumulates in Fabry disease (agalactosidase deficiency) (Handa et al., 1971) (Harzer et al., 1989) . Studies by Trinchera et al. (1990) on rat liver have indicated that, in that tissue, glycosphingolipids must be metabolized to sphingosine before recycling of the long-chain base to sphingomyelin can occur, whereas recycling for ganglioside synthesis can take place at the level of glucosylceramide. Breakdown of ceramide would also have to occur for labelled fatty acids to be incorporated into phospholipids. We believe the decreased incorporation of radioactivity from metabolized lactosylceramide into biosynthetic products may reflect the defect in ceramide catabolism in this disorder; however, we cannot exclude the possibility that prosaposin, or its products, has some other function. Morimoto et al. (1989) proposed that saposin A has similar properties to SAP-2, in tha-t both activate ,3-galactocerebrosidase and /3-glucocerebrosidase in vitro. If this applies in vivo, one might expect that each of these activators could compensate for the other. However, Fabbro & Grabowski (1991) have shown that saposin A and SAP-2 have a synergistic effect on fglucocerebrosidase under their assay conditions. This might explain why the two individuals with apparently isolated SAP-2 deficiencies [Christomanou et al. (1986 (Morimoto et al., 1988) have been reported to be stimulatory. Christomanou & Kleinschmidt (1985) have suggested that the former may act by solubilizing the substrate, whereas saposin D had its effect in the presence of detergent (Morimoto et al., 1988 Evidence now suggests that a single neuraminidase enzyme is responsible for the lysosomal degradation of gangliosides and oligosaccharides (Mancini et al., 1986; Zeigler et al., 1989; Leiser et al., 1989; Hiraiwa et al., 1987) and our data indicate that the activity of this enzyme is normal in our patient [workers in Dr. Sandhoff's laboratory (Schnabel et al., 1992) have also found a normal lysosomal neuraminidase activity using a different assay procedure]. This observation and the findings of Hiraiwa et al.
(1991) clearly argue against the hypothesis of Potier et al. (1990) that the prosaposin gene codes for lysosomal neuraminidase. Although the lysosomal neuraminidase activity was normal in our patient's cells, GM1 ganglioside-loading studies have indicated that there is an impairment in the turnover of GM3 ganglioside in cells from this patient and also in cells from a patient with SAP-1 deficiency (Schmid et al., 1992 Our findings have clearly demonstrated that studies on patients with a defective SAP(s) can teach us much about the physiological role of that SAP(s). As a caveat, it should be noted that certain activities observed in vitro may not play a role in vivo. In part, this may reflect the detergent-like properties of the saposins. SAP-I has been shown to solubilize a number of sphingolipid substrates, and the sequence similarities to the other saposins indicate that they also have potential detergent-like properties. It is possible that such properties may be elicited in vitro but not in vivo. Also, substrate-loading studies may give misleading results depending on the level of residual enzyme activity and/or the amount of substrate added.
In prosaposin deficiency the effects of the defect are profound, with the catabolism of several sphingolipids adversely affected. If the unprocessed gene product has a physiological role as well, perhaps in sphingolipid transport or cell regulation, its function must also be deficient in this disorder. O'Brien et al. (1988) reported that there were higher concentrations of the highmolecular mass forms of prosaposin in human brain and testis than in kidney, spleen or liver, so any defect related to the function of the precursor protein is more likely to be manifested in the former tissues. The precursor forms of prosaposin may also have a function in extracellular fluids (Hineno et al., 1991 
